At ACM CHIL 2021, the company presented study results on a model of simultaneously optimizing multiple properties of molecules with enhanced performance by nearly double compared to models of Google-Stanford University and MIT It can be used for optimizing molecule design in pre-clinical and clinical stage
SEOUL, South Korea--(BUSINESS WIRE)-- Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference and Learning (ACM CHIL) 2021. The CMG technology can optimize multiple properties of molecules simultaneously.